CR Sanjiu Q1 2026: Revenue Jumps 18.6% but Net Profit Slips 9.1%; Cash Outflow Weighs on China Resources Pharmaceutical Subsidiary

Bulletin Express04-24

China Resources Pharmaceutical Group Limited (CHINARES PHARMA, 03320) disclosed unaudited first-quarter results of its 63.22%-owned subsidiary, CR Sanjiu, for the three months ended 31 March 2026.

Revenue and Earnings • Revenue rose to RMB 8.13 billion, up 18.60% from RMB 6.85 billion a year earlier, reflecting solid top-line momentum. • Net profit declined 9.17% year on year to RMB 1.21 billion, compared with RMB 1.33 billion in Q1 2025, indicating margin pressure despite higher sales.

Cash Flow and Liquidity • Net cash used in the quarter was RMB 1.32 billion, reversing from an inflow of RMB 1.25 billion in the prior-year period. • Cash and cash equivalents ended the quarter at RMB 3.20 billion, down 47.63% from RMB 6.11 billion a year earlier.

Balance-Sheet Movements (31 Mar 2026 vs 31 Dec 2025) • Total assets slipped 1.12% to RMB 58.14 billion. • Total liabilities fell 9.16% to RMB 18.47 billion, improving the leverage profile. • Owner’s equity increased 3.13% to RMB 39.68 billion, driven by retained earnings.

Compliance Note The figures are prepared under PRC GAAP and have not been reviewed or audited; adjustments may arise upon audit. The data relate solely to CR Sanjiu and do not present the consolidated position of China Resources Pharmaceutical Group Limited. Shareholders and potential investors are advised to exercise caution when interpreting these unaudited results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191964789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191964789","market":"hk","top_or_hot":-1,"title":"CR Sanjiu Q1 2026: Revenue Jumps 18.6% but Net Profit Slips 9.1%; Cash Outflow Weighs on China Resources Pharmaceutical Subsidiary","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (CHINARES PHARMA, 03320) disclosed unaudited first-quarter results of its 63.22%-owned subsidiary, CR Sanjiu, for the three months ended 31 March 2026.</p>\n<p>Revenue and Earnings  \n• Revenue rose to RMB 8.13 billion, up 18.60% from RMB 6.85 billion a year earlier, reflecting solid top-line momentum.  \n• Net profit declined 9.17% year on year to RMB 1.21 billion, compared with RMB 1.33 billion in Q1 2025, indicating margin pressure despite higher sales.</p>\n<p>Cash Flow and Liquidity  \n• Net cash used in the quarter was RMB 1.32 billion, reversing from an inflow of RMB 1.25 billion in the prior-year period.  \n• Cash and cash equivalents ended the quarter at RMB 3.20 billion, down 47.63% from RMB 6.11 billion a year earlier.</p>\n<p>Balance-Sheet Movements (31 Mar 2026 vs 31 Dec 2025)  \n• Total assets slipped 1.12% to RMB 58.14 billion.  \n• Total liabilities fell 9.16% to RMB 18.47 billion, improving the leverage profile.  \n• Owner’s equity increased 3.13% to RMB 39.68 billion, driven by retained earnings.</p>\n<p>Compliance Note  \nThe figures are prepared under PRC GAAP and have not been reviewed or audited; adjustments may arise upon audit. The data relate solely to CR Sanjiu and do not present the consolidated position of China Resources Pharmaceutical Group Limited. Shareholders and potential investors are advised to exercise caution when interpreting these unaudited results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Sanjiu Q1 2026: Revenue Jumps 18.6% but Net Profit Slips 9.1%; Cash Outflow Weighs on China Resources Pharmaceutical Subsidiary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Sanjiu Q1 2026: Revenue Jumps 18.6% but Net Profit Slips 9.1%; Cash Outflow Weighs on China Resources Pharmaceutical Subsidiary\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-24 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (CHINARES PHARMA, 03320) disclosed unaudited first-quarter results of its 63.22%-owned subsidiary, CR Sanjiu, for the three months ended 31 March 2026.</p>\n<p>Revenue and Earnings  \n• Revenue rose to RMB 8.13 billion, up 18.60% from RMB 6.85 billion a year earlier, reflecting solid top-line momentum.  \n• Net profit declined 9.17% year on year to RMB 1.21 billion, compared with RMB 1.33 billion in Q1 2025, indicating margin pressure despite higher sales.</p>\n<p>Cash Flow and Liquidity  \n• Net cash used in the quarter was RMB 1.32 billion, reversing from an inflow of RMB 1.25 billion in the prior-year period.  \n• Cash and cash equivalents ended the quarter at RMB 3.20 billion, down 47.63% from RMB 6.11 billion a year earlier.</p>\n<p>Balance-Sheet Movements (31 Mar 2026 vs 31 Dec 2025)  \n• Total assets slipped 1.12% to RMB 58.14 billion.  \n• Total liabilities fell 9.16% to RMB 18.47 billion, improving the leverage profile.  \n• Owner’s equity increased 3.13% to RMB 39.68 billion, driven by retained earnings.</p>\n<p>Compliance Note  \nThe figures are prepared under PRC GAAP and have not been reviewed or audited; adjustments may arise upon audit. The data relate solely to CR Sanjiu and do not present the consolidated position of China Resources Pharmaceutical Group Limited. Shareholders and potential investors are advised to exercise caution when interpreting these unaudited results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1191964789","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191964789","pubTimestamp":1777029925,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (CHINARES PHARMA, 03320) disclosed unaudited first-quarter results of its 63.22%-owned subsidiary, CR Sanjiu, for the three months ended 31 March 2026....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润三九2026年第一季度：营收增长18.6%，净利润下滑9.1%；现金流出拖累华润医药子公司","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (CHINARES PHARMA, 03320) disclosed unaudited first-quarter results of its 63.22%-owned subsidiary, CR Sanjiu, for the three months ended 31 March 2026.\nRevenue and Earnings  \n• Revenue rose to RMB 8.13 billion, up 18.60% from RMB 6.85 billion a year earlier, reflecting solid top-line momentum.  \n• Net profit declined 9.17% year on year to RMB 1.21 billion, compared with RMB 1.33 billion in Q1 2025, indicating margin pressure despite higher sales.\nCash Flow and Liquidity  \n• Net cash used in the quarter was RMB 1.32 billion, reversing from an inflow of RMB 1.25 billion in the prior-year period.  \n• Cash and cash equivalents ended the quarter at RMB 3.20 billion, down 47.63% from RMB 6.11 billion a year earlier.\nBalance-Sheet Movements (31 Mar 2026 vs 31 Dec 2025)  \n• Total assets slipped 1.12% to RMB 58.14 billion.  \n• Total liabilities fell 9.16% to RMB 18.47 billion, improving the leverage profile.  \n• Owner’s equity increased 3.13% to RMB 39.68 billion, driven by retained earnings.\nCompliance Note  \nThe figures are prepared under PRC GAAP and have not been reviewed or audited; adjustments may arise upon audit. The data relate solely to CR Sanjiu and do not present the consolidated position of China Resources Pharmaceutical Group Limited. Shareholders and potential investors are advised to exercise caution when interpreting these unaudited results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191964789","isCrawlerRequest":true}